Stakeholders call for new Medicare payment plans to be withdrawn

May 12, 2016
Stakeholders call for new Medicare payment plans to be withdrawn

Earlier this week, Astellas submitted to the Centers for Medicare and Medicaid Services (CMS) comments on the agency’s Medicare Part B drug payment model proposed rule. Joining many organizations across the healthcare spectrum, our comments outline a number of concerns with the proposal as written and urge the agency to withdraw the proposed rule.

Most notably, our comments point to unintended consequences of the proposed rule that, if implemented, would threaten access to needed medicines for Medicare beneficiaries and deter future innovation in areas of unmet medical need.

We also outline several ways in which the proposal is inconsistent with underlying statute and exceeds CMS’ authority. For example, we observe that the proposed rule fails to include care quality measures or outcomes metrics, contrary to statute which specifies that Center for Medicare and Medicaid Innovation (CMMI) models must maintain or improve care quality.

Please find our full comments here.

Stakeholders call for new Medicare payment plans to be withdrawn

Karl Uhlendorf is director of communications and stakeholder engagement at Astellas Pharma US, Inc. With a 20-year track record of leading diverse public affairs and editorial teams, he currently oversees Astellas’ government communications and stakeholder engagement program.

Prior to joining Astellas in 2014, Karl was vice president of communications and public affairs at the Pharmaceutical Research & Manufacturers of America (PhRMA), responsible for communications strategy and execution in support of the association’s federal and state advocacy priorities. During his eight years at PhRMA, he assumed roles of increasing responsibility and scope.

Prior to joining PhRMA, Karl was editorial director at FDC Reports/Elsevier Business Intelligence, publisher of “The Pink Sheet” and other leading trade publications dedicated to FDA-regulated industries. He began his career as a reporter covering biomedical research and health policy, parlaying the experience into a series of editorial leadership positions.

Karl is actively engaged with a wide array of health-related organizations, including PhRMA, the Biotechnology Innovation Organization, National Pharmaceutical Council, National Consumers League, HealthyWomen, WomenHeart, Research!America and Caregivers Action Network. He graduated with a Bachelor of Literature degree from Bates College in Lewiston, Maine.

Leave a Reply